Status: Not yet recruiting
Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older
This phase 1 study in China will evaluate the Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Participants needed: 128
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Yikang Biotech (Suzhou) Co., Ltd.Updated: Sep 8, 2026Locations: 1
Eligibility criteria
Adults aged 18 years and older who reside in the local area and can provide lega... [+3]
Abnormal pre-vaccination laboratory tests (complete blood count, blood biochemis... [+21]